anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Thermoregulation is a major problem for low birth weight infants. The EPICure study showed that 36% of infants born between 24 and 25 weeks gestation had an admission temperature less than 35 degrees Celsius. Hypothermia is associated with increased risk of morbidity and mortality. The HeLP trial hopes to address these issues with the use of a polyethylene occlusive wrap applied immediately after delivery to infants born at less that 28 weeks gestation. Forty-five centers are currently involved in this study. Infant enrollments began in December 2004.

Primary outcome: To determine if polyethylene occlusive wrap applied immediately after delivery to infants born between 24+0 and 27+6 weeks gestation results in decreased mortality compared with the conventional method of drying. Because of increased mortality and variable center specific resuscitation practices, infants born at less than 24 weeks gestation will be randomized as part of a separate Pilot Study and centers may choose if they wish to participate in this group or not. Secondary outcome: The key secondary outcome will be axillary temperature taken on introduction into a warm environment in the NICU. We will also record clinically important variables including: acidosis, hypotension, hypoglycaemia, seizures, patent ductus arteriosus, respiratory distress syndrome/chronic lung disease, necrotizing enterocolitis and head ultrasound results. Length of stay and cause of death at discharge will also be recorded. Long-term follow-up is critical to our understanding of the implications of any new intervention. As such, we ask parents from hospitals who agree to participate in the follow-up study for permission to contact them approximately 18 months after birth.

Preterm infants meeting the eligibility criteria will be randomly assigned within three gestational age strata (less than 24 weeks, 24+0 to 25+6 weeks gestation, and 26+0 to 27+6 weeks gestation) to either the occlusive skin wrap group or the standard of care (non-wrap) group.
Patients receive Akt inhibitor MK2206 PO QOD of a 28-day course, and erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Participants will be administered 35-40 FMT capsules orally with water, for a total dose of 80-100g. This will only occur once and takes approximately 30 minutes.
Following a safety review of the first three subjects receiving 0.4 mg dose, the remaining 22 subjects will receive the full 1.2 mg dose of KSP-910638G reconstituted in 5 mL 0.9% NaCl. These 22 subjects will receive all 5 mL of the peptide solution in a syringe for administration. The agent will not be reconstituted until the subject is ready to squirt the peptide into his or her mouth via syringe. They will be asked to wait 5 minutes and then drink at least 4-8 oz of tap water.
The invention provides a five-ester soft capsule and a preparation method thereof. The content is kadsura longepedunculata extract. The preparation of the five-ester soft capsule comprises the following steps: step one: and (3) carrying out enzymolysis on the dried schisandra chinensis fruits by adopting cell wall decomposing enzyme, keeping the enzymolysis liquid for later use, and carrying out reflux extraction on enzymolysis residues for 2 times and combining the enzymolysis liquid to obtain a mixed liquid for later use. Step two: concentrating the mixed solution at 50-60deg.C under reduced pressure to relative density of 1.28-1.32, and recovering ethanol to obtain kadsura pepper fruit ethanol extract. Step three: injecting the kadsura longepedunculata alcohol extract into the hollow capsule shell to obtain the five-ester soft capsule. The invention adopts cell wall decomposing enzyme to decompose cellulose, lignin and pectin in the cell wall of the fruit of the kadsura longepedunculata, and damages the structure of the cell wall of the fruit of the kadsura longepedunculata, so that the lignan compounds in the cell are easier to extract. Meanwhile, the cell wall decomposing enzyme can promote the breaking of cell walls and the dissociation of cells, so that the extraction process is faster and more effective.
PURPOSE:To prevent the destruction of liposome caused by the attack with the phospholipase in the living body, and to enable the selective and concentrated transfer of drug to the aimed organ, by covering the surface of a liposome membrane with an ester of polysaccharide and fatty acid. CONSTITUTION:The surface of a single-layered or multi-layered liposome membrane composed of only a lipid (e.g. phosphatidylcholine) or of lipid and sterol, is coated with the ester of a polysaccharide (e.g. dextran, amylopectine, pullulan, chitosan, etc.) and fatty acid (e.g. lauric acid, myristic acid, palmitic acid, stearic acid, etc.). The coating can be carried out by adding an aqueous solution containing said ester to an aqueous solution containing liposome, and stirring the mixture.
Strain 19 of Brucella abortus is produced by culturing the microorganism in an aerated, sterile, aqueous medium containing glucose, yeast extract, sodium chloride, thiamine hydrochloride, anti-foaming agent and a proteinaceous material which is a pancreatic enzyme hydrolysate of casein; the aeration being provided by passing sterile air into the lower portion of the fermenter tank below the surface of the nutrient medium and at a rate of at least 7 parts by volume per minute for each 10 parts by volume of the medium and agitation of the medium is obtained during the culture. Temperature of cultivation is 36-38  DEG C. and duration 20-40 hours. Preferably the operation is carried out in two stages, (a) an initial culture stage of 20 hours, (b) a second culture stage of 15-20 hours after the introduction of fresh liquid medium, preferably in an amount at least equal to the amount of liquid medium initially employed. The preferred anti-foaming agent is a propylene glycol, preferably having a molecular weight of from 1500-3000. After harvesting, the vaccine concentrate is mixed with buffered physiological saline or other injectable diluent or is freeze dried in the presence of a stabilizer. A preferred stabilizer consists of an aqueous solution containing potassium citrate monohydrate, sodium citrate, dipotassium acid phosphate, calcium chloride, magnesium chloride hexahydrate, potassium carbonate sesquihydrate and lactose.ALSO:A vaccine concentrate of strain 19 of Brucella abortus is produced by culturing the microorganisms in an aerated, sterile, aqueous medium containing glucose, yeast extract, sodium chloride, thiamine hydrochloride, antifoaming agent and a proteinaceous material which is a pancreatic enzyme hydrolysate of casein; the aeration being provided by passing sterile air into the lower portion of the fermenter tank below the surface of the nutrient medium and at a rate of at least 0.7 volume per minute for each volume of the liquid medium, which is agitated during the cultivation step.  The liquid is maintained at a temperature of from 36 DEG  to 38 DEG  C. for 20 to 40 hours. Preferably the operation is carried out in two stages, (a) an initial culture stage of 20 hours, (b) a second culture stage of 15 to 20 hours after the introduction of fresh liquid medium, preferably in an amount at least equal to the amount of liquid medium initially employed. The preferred antifoaming agent is a propylene glycol, preferably having a molecular weight of from 1500 to 3000.  After harvesting, the vaccine concentrate is mixed with buffered physiological saline or other injectable diluent or is freeze dried in the presence of a stabilizer, expecially one consisting essentially of an aqueous solution containing potassium citrate monohydrate, sodium citrate, dipotassium acid phosphate, calcium chloride, magnesium chloride hexahydrate, potassium carbonate sesquihydrate and lactose preferably in an amount, respectively, of 0.135, 0.245, 0.061, 0.133, 0.06, 0.1 and 17.25% by weight, the balance being water.
Control group patients initially receive usual standard of (traditional) endoscopic treatment (SET) as defined by injection therapy with another modality or sole/combination use of thermal or mechanical modalities. Crossovers to either treatment arm are permitted if immediate haemostasis does not achieved with standard endoscopic or TC-325 application.Treatment failure of SET is defined as endoscopists cannot achieve hemostasis by selected SET.
A patch and sensor assembly for use in an EP mapping system has two portions: a reusable portion and a disposable portion. The reusable portion houses the biosensors used in magnetic based location and mapping systems and the electrical lead necessary to communicate between the biosensor and the mapping system. The reusable portion may also contain a portion of the electrode necessary to receive electrical signals from the body of the patient. The disposable portion of the patch and sensor assembly contains an adhesive covered flexible patch having at least a portion of the electrode used to receive electrical signals from the body of the patient and may contain the electrical lead necessary to communicate such an electrical signal to the mapping system. The disposable portion contains a receptacle adapted to receive and mechanically secure the reusable portion to the disposable portion of the assembly. Such a patch and sensor assembly is useful in hybrid magnetic and impedance based location and mapping systems such as those used in electrophysiology.
Approximately 51 subjects will be assigned to albiglutide 30 mg weekly (with treatment-masked increase to 50 mg weekly at Week 6) + background insulin. The starting dose of albiglutide will be 30 mg once weekly and will be increased at Week 6 to 50 mg, once weekly, if the 30-mg weekly dose is tolerated.
Disclosed are systems, methods, and non-transitory computer-readable media for automated behavioral and physiological testing of untethered testing animals. An automated behavioral testing system communicates with electronic devices attached to testing animals to provide automated physiological measurements and perturbations. The electronic devices are wirelessly charged to eliminate the need to remove the electronic devices during the course of the study. The automated behavioral testing system includes a filtering chamber positioned between a housing chamber and a behavioral testing chamber. The filtering chamber provides a passageway between the housing chamber and the behavioral testing chamber used to manage access to the behavioral testing chamber. For example, a gate component implemented between the filtering chamber and the behavioral testing chamber can be configured into either a closed configuration to restrict access between the filtering chamber and the behavioral testing chamber, or an open configuration to permit between the filtering chamber and the behavioral testing chamber.
FIELD: pharmaceutics. SUBSTANCE: it is suggested a new inactivator of uracil-reductase - 5-ethynyluracil. It enhances the action of 5-fluouracil and is used in treating the cancer. It is, also, suggested to apply pharmaceutical composition based upon 5-ethynyluracil and the method for its obtaining. Pharmaceutical combination is suggested to enhance the action or decrease the toxicity of 5- fluouracil. Such a combination contains separate or mixed components of 5-ethyluracil and 5-fluouracil or its promedicine for simultaneous, separate or successive injection. EFFECT: increased number of activators. 16 cl, 2 dwg, 8 ex, 1 tbl
Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is used in case of potentially reversible cardiac failure and restores systemic hemodynamics. However, whether this is followed by improvement of microcirculatory perfusion is unknown. Moreover, critically ill patients have possible pre-existing microcirculatory perfusion disturbances. Therefore, this review provides an overview of alterations in sublingual microcirculatory perfusion in critically ill adult patients receiving VA-ECMO support. Pubmed, Embase (Ovid), Cochrane Central Register of Controlled Trials, and Web of Science were systematically searched according to PRISMA guidelines. Studies reporting sublingual microcirculatory perfusion measurements in adult patients supported by VA-ECMO were included. Outcome parameters included small vessel density (SVD), perfused vessel density (PVD), perfused small vessel density (PSVD), proportion of perfused vessels (PPV), microvascular flow index (MFI) and the heterogeneity index (HI). The protocol was registered at PROSPERO (CRD42021243930). The search identified 1215 studies of which 11 were included. Cardiogenic shock was the most common indication for VA-ECMO (n=8). Three studies report increased PSVD, PPV, and MFI 24 hours after initiation of ECMO compared to pre-ECMO. Nonetheless, microcirculatory perfusion stabilized thereafter. Four out of four studies showed higher PSVD and PPV in survivors compared to non-survivors. Over time, survivors showed recovery of microcirculatory perfusion within hours of initiation of ECMO, whereas this was absent in non-survivors. Notwithstanding the limited sample, VA-ECMO seems to improve microcirculatory perfusion shortly after initiation of ECMO, especially in survivors. Further research in larger cohorts is needed to clarify the longitudinal effects of ECMO on microcirculatory perfusion.
Baseline positive pressure ventilation skill assessment of all study participants: Site principal investigators will recruit eligible providers for the trial. Participants will fill out study enrollment sheet which will ask for 1. Demographic information 2. Profession 3. Experience (number of times positive pressure ventilation performed on a newborn in the last 6 months) 4. Last time Neonatal Resuscitation Program course attended and 5. Institution. Participants will perform 1 minute of positive pressure ventilation on the cart. During this baseline assessment, there is no audio-visual feedback or display. The cart will record data on mask leak, pressure used, ventilation rate, head positioning.

Pre-randomization Standardized Instructor Led Skills Training: All study participants will undergo the standard instructor-led positive pressure ventilation skills training. Each site will have a designated study instructor who will remain blinded to the baseline positive pressure ventilation skill assessment data. Study instructors will use a standardized script as a guide for the instructor led positive pressure ventilation skills training. This training will occur with the same manikin and equipment as the one available at the cart. This training will decrease the impact of variability in prior training received by the study participants.

Post- Instructor led positive pressure ventilation skills training Assessment: Immediately after the instructor led training, participants will perform 1-minute positive pressure ventilation on the cart. This will also be a blinded assessment without any display or feedback. Comparison of pre- and post- instructor led training assessments will provide unique data to evaluate if instructor led training changes the positive pressure ventilation skills.

Randomization with minimization procedure: Randomization will be provided by a secure website using the computer-generated randomization and the minimization procedure. The goal of the minimization procedure is to prevent an imbalance of factors that may influence positive pressure ventilation skill retention. Factors that will be taken into account during minimization procedure are

1. PPV skill proficiency during baseline pre-instructor led training assessment: Based on the pre-training skill assessment, each participant will be coded as a Group A \[Proficient\] or Group B \[not proficient\]. Participants will be considered proficient if participants are able to achieve low mask leak (\< 30%) on \>80% of ventilations provided. Only study Principal investigator and research nurse will have access to this data. 2. Profession 3. Experience (number of times positive pressure ventilation performed on a newborn in the last 6 months) 4. Last time NRP course attended and 5. Institution. Based on this information, the randomization website will assign them to the intervention (booster training) or control group (no booster training) with 1:1 allocation.
The invention includes methods for prophylaxis of at least one of infection with HIV/AIDS and venereal diseases, grippe/influenza. The method includes use of materials, in solution, cream, gel and/or tablet form, which possess virucidal and bactericidal characteristics. The method includes applying such materials to a mammal's skin and/or mucous membranes in solution and/or cream or gel form. Also provided is a method applying such materials to the mouth and/or throat and nose for inhalation for prevention of and/or treatment of grippe and influenza. One such solution is an aqueous solution that includes about 0.1 to about 0.3 percent by weight pantoprazole or a derivative thereof, about 2 percent to about 4 percent by weight sodium chloride, about 0.1 percent to about 5 percent by weight sodium hydrocarbonate, and 0 percent to about 1 percent sodium tetraborate. Creams or gels including pantoprazole may also be used.
BACKGROUND: Acute kidney injury (AKI) is a recognized comorbidity in pediatric diabetic ketoacidosis (DKA), although the exact etiology is unclear. The unique physiology of DKA makes dehydration assessments challenging, and these patients potentially receive excessive amounts of intravenous fluids (IVF). We hypothesized that dehydration is over-estimated in pediatric DKA, leading to over-administration of IVF and hyperchloremia that worsens AKI.
METHODS: Retrospective cohort of all DKA inpatients at a tertiary pediatric hospital from 2014 to 2019. A total of 145 children were included; reasons for exclusion were pre-existing kidney disease or incomplete medical records. AKI was determined by change in creatinine during admission, and comparison to a calculated baseline value. Linear regression multivariable analysis was used to identify factors associated with AKI. True dehydration was calculated from patients' change in weight, as previously validated. Fluid over-resuscitation was defined as total fluids given above the true dehydration.
RESULTS: A total of 19% of patients met KDIGO serum creatinine criteria for AKI on admission. Only 2% had AKI on hospital discharge. True dehydration and high serum urea levels were associated with high serum creatinine levels on admission (p = 0.042; p < 0.001, respectively). Fluid over-resuscitation and hyperchloremia were associated with delayed kidney recovery (p < 0.001). Severity of initial AKI was associated with cerebral edema (p = 0.018).
CONCLUSIONS: Dehydration was associated with initial AKI in children with DKA. Persistent AKI and delay to recovery was associated with hyperchloremia and over-resuscitation with IVF, potentially modifiable clinical variables for earlier AKI recovery and reduction in long-term morbidity. This highlights the need to re-address fluid protocols in pediatric DKA.
Intercellular communication often relies on exosomes as messengers and is critical for cancer metastasis in hypoxic tumor microenvironment. Some circular RNAs (circRNAs) are enriched in cancer cell-derived exosomes, but little is known about their ability to regulate intercellular communication and cancer metastasis. Here, by systematically analyzing exosomes secreted by non-small cell lung cancer (NSCLC) cells, a hypoxia-induced exosomal circPLEKHM1 is identified that drives NSCLC metastasis through polarizing macrophages toward to M2 type. Mechanistically, exosomal circPLEKHM1 promoted PABPC1-eIF4G interaction to facilitate the translation of the oncostatin M receptor (OSMR), thereby promoting macrophage polarization for cancer metastasis. Importantly, circPLEKHM1-targeted therapy significantly reduces NSCLC metastasis in vivo. circPLEKHM1 serves as a prognostic biomarker for metastasis and poor survival in NSCLC patients. This study unveils a new circRNA-mediated mechanism underlying how cancer cells crosstalk with macrophages within the hypoxic tumor microenvironment to promote metastasis, highlighting the importance of exosomal circPLEKHM1 as a prognostic biomarker and therapeutic target for lung cancer metastasis.
The invention relates to an animal agent with heat clearing and detoxicating, while it can diminish the inflammation and reduce the pain. Wherein, it uses creat as material; and the production comprises that cleaning the creat, cutting and broking; extracting it in the water at 8 mass times than drug, while the extracting temperature is 95+-3Deg. C; in the first time, extracting with 10% acid to adjust the pH value to 2-5, to be boiled for 2 hours; in the second time, adding water that 8 times of drug, using 10% alkali to adjust the pH value to 8-9, and extracting for 1.5hours; filtering and combining the solution, then drying and broking into creat powder. The invention can effectively treat animal disease. The invention uses water extraction and adds acid before adding alkali to keep the effective component of drug. And it can improve the breeding benefit and reduce the production cost of drug.
The exercise-induced muscle damage is associated with eccentric activities affecting muscle structural unit through micro-injury that can promote a local inflammatory response, muscle damage and delayed onset muscle soreness. These events can cause an impact on athletic performance and lower adherence to the training programs. To optimize muscle recovery after the damage caused by exercise is essential to ensure adequate caloric intake , with required amounts of macronutrients and micronutrients. Recent studies have been showed that the protein intake before sleeping is a effective strategy to inhibit muscle protein degradation, stimulate muscle protein synthesis and facilitate adaptive response of skeletal muscle to physical exercise. Furthermore, evidences on the use of anti-inflammatory nutrients have suggested that diets rich in omega 3 can reduce inflammation through inhibition of pro-inflammatory mediators. Therefore, the intake of this nutrient combined with a protein meal before sleeps and the control of food intake can improve adherence to sports training. The study will consist of three groups where everyone will receive an individualized diet. A randomization procedure will determine the type of intervention. The distribution of the groups will be as follows: group 1 (control) - volunteers follow individualized diet and olive oil capsules and maltodextrin; group 2 - intervention with omega 3 more individualized diet ; group 3 - omega 3 and whey protein isolate intervention more individualized diet.

The order of procedures to be performed will be: (1) Nutritional and Anthropometric assessment; (2) Individual orientation of diet and distribution of supplements; (3) Baseline assessment (peak torque, muscle pain levels and vastus lateralis and rectus femoris echo intensity; (4) Muscle damage induction by eccentric exercise protocol; (5) Reviews after 24h, 48h, 72h, which will follow the routine and the methods applied at baseline.